News Neurogene Inc.

Equities

NGNE

US64135M1053

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 13/02/2026 GMT			5-day change	1st Jan Change
17.38 ^USD	+2.24%		+0.87%	-15.63%

02-04	Neurogene announces inducement grant under Nasdaq Listing Rule	RE
01-12	Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-In-Class Gene Therapy for Rett Syndrome	CI

All News

02-05	Neurogene to Participate in Upcoming Investor Conferences	BU
02-04	Neurogene announces inducement grant under Nasdaq Listing Rule	RE
02-04	Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	BU
01-14	Neurogene : 2026 JP Morgan Presentation	PU
01-12	Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-In-Class Gene Therapy for Rett Syndrome	CI
01-12	Neurogene : Corporate Presentation January 2026	PU
01-12	Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome	BU
01-05	Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference	BU
12-04	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
11-13	Neurogene : 202511 NGNE Corporate Presentation	PU
11-13	Neurogene: Q3 Earnings Snapshot	AQ
11-13	Gene therapy developer Neurogene's Q3 net loss widens	RE
11-13	Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates	BU
11-13	Neurogene Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-13	Neurogene Inc. Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome Multidomain	CI
11-12	Neurogene : NGN 401 2H25 Update FINAL	PU
11-12	Neurogene Inc. Presents at Stifel 2025 Healthcare Conference, Nov-12-2025 04:40 PM
11-12	Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome	BU
11-06	Neurogene Doses First Patient in Registrational Trial of NGN-401 for Rett Syndrome	MT
11-06	Neurogene : 202511 NGNE Corporate Presentation FINAL	PU
11-06	Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome	BU
11-06	Neurogene Inc. Announces First Participant Dosed in Embolden?? Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome	CI
11-05	Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	BU
09/10/25	Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Fourth Quarter of 2025	CI
09/10/25	Neurogene Shares Rise After NGN-401 Discussions With FDA	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

News Neurogene Inc.

Equities

NGNE

US64135M1053

Biotechnology & Medical Research

All News

Filters